[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] #  $jbios Jefferies initiates coverage on $JBIO with a buy rating, citing the potential of its IgAN treatment. The stock is expected to see positive movement due to the positive outlook. ### About $jbios JBIO refers to a biotechnology company, likely focused on pharmaceutical research and development. **Top assets mentioned** In the posts about $jbios in the last XX hours [Vertex Protocol (VRTX)](/topic/$vrtx) [Vertex Protocol (VRTX)](/topic/vertex-protocol) [Vertex Pharmaceuticals Incorporated (VRTX)](/topic/vertex-pharma) **Top topics mentioned** In the posts about $jbios in the last XX hours [$otskf](/topic/$otskf), [$vrtx](/topic/$vrtx), [$jbio](/topic/$jbio), [vertex protocol](/topic/vertex-protocol), [vertex pharma](/topic/vertex-pharma), [coins exchange tokens](/topic/coins-exchange-tokens), [coins base ecosystem](/topic/coins-base-ecosystem), [stocks healthcare](/topic/stocks-healthcare), [coins arbitrum](/topic/coins-arbitrum) ### Top Social Posts [#](/topic/$jbios/posts) --- Top posts by engagements in the last XX hours *Showing only X posts for non-authenticated requests. Use your API key in requests for full results.* "Jefferies🏁 $JBIO Buy-$16 $VRTX $OTSKF Jefferies said in its initiation report: "We like $JBIO's long-acting anti-APRIL (JADE101) in IgAN: 1) our PK work suggests '101 can achieve Q8/12W dosing 2) we think efficacy will be as good as povetacicept w/ pot'l upside on % clinical remission 3) we expect tolerable safety profile w/o increased serious infections 4) we see oppty for disease modifying tx w/ longer dosing interval in IgAN. We model $915M risk-adj. PS for '101 (POS 30%). Co also has $255M cash/cash eq. w/ runway to '27."" [@Quantumup1](/creator/x/Quantumup1) on [X](/post/tweet/1944835951676494032) 2025-07-14 19:06:38 UTC 3517 followers, 1061 engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
$jbios
Jefferies initiates coverage on $JBIO with a buy rating, citing the potential of its IgAN treatment. The stock is expected to see positive movement due to the positive outlook.
About $jbios
JBIO refers to a biotechnology company, likely focused on pharmaceutical research and development.
Top assets mentioned In the posts about $jbios in the last XX hours
Vertex Protocol (VRTX) Vertex Protocol (VRTX) Vertex Pharmaceuticals Incorporated (VRTX)
Top topics mentioned In the posts about $jbios in the last XX hours
$otskf, $vrtx, $jbio, vertex protocol, vertex pharma, coins exchange tokens, coins base ecosystem, stocks healthcare, coins arbitrum
Top Social Posts #
Top posts by engagements in the last XX hours
Showing only X posts for non-authenticated requests. Use your API key in requests for full results.
"Jefferies🏁 $JBIO Buy-$16 $VRTX $OTSKF Jefferies said in its initiation report: "We like $JBIO's long-acting anti-APRIL (JADE101) in IgAN: 1) our PK work suggests '101 can achieve Q8/12W dosing 2) we think efficacy will be as good as povetacicept w/ pot'l upside on % clinical remission 3) we expect tolerable safety profile w/o increased serious infections 4) we see oppty for disease modifying tx w/ longer dosing interval in IgAN. We model $915M risk-adj. PS for '101 (POS 30%). Co also has $255M cash/cash eq. w/ runway to '27.""
@Quantumup1 on X 2025-07-14 19:06:38 UTC 3517 followers, 1061 engagements